BiomX Inc.
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development (“R&D”) expenses, net | $21.3M-13.7% | $24.7M+47.7% | $16.7M+2.8% | $16.2M-28.4% | $22.7M |
| General and administrative expenses | $9.6M-18.2% | $11.8M+36.1% | $8.7M-8.5% | $9.5M-16.1% | $11.3M |
| Gain from early lease termination | -$2.9M | — | — | — | — |
| Goodwill impairment | $801K | — | — | — | — |
| IPR&D impairment | $11.8M+265.8% | $3.2M | — | — | — |
| Other long-lived assets impairment | $1.7M-59.1% | $4.0M | — | — | — |
| Operating loss | $41.5M-6.9% | $44.5M+75.6% | $25.3M-6.9% | $27.2M-23.2% | $35.5M |
| Other expense (income) | $93K+104.3% | -$2.1M-500.3% | -$357K-166.4% | -$134K | — |
| Interest expenses | $20K-97.7% | $873K-63.7% | $2.4M+16.2% | $2.1M+196.0% | $699K |
| Finance expense , net | $724K-21.2% | $919K | — | — | — |
| Income from change in fair value of warrants | -$6.1M+76.9% | -$26.5M | — | — | — |
| Loss before tax | $36.2M+104.3% | $17.7M-32.2% | $26.1M-7.5% | $28.3M-21.9% | $36.2M |
| Tax expenses | $7K-46.2% | $13K-43.5% | $23K-64.6% | $65K-3.0% | $67K |
| Net Loss | $36.2M+104.2% | $17.7M-32.3% | $26.2M-7.6% | $28.3M-21.8% | $36.2M |
| Basic loss per share of Common Stock (in Dollars per share) | $22190.00-12.5% | $25370.00+397.5% | $5100.00+436.8% | $950.00-31.7% | $1390.00 |
| Diluted loss per share of Common Stock (in Dollars per share) | $22190.00-61.9% | $58310.00+1043.3% | $5100.00 | — | — |
| Weighted average number of shares used in computing basic loss per share of Common Stock (in Shares) | $1631037000.00+133.4% | $698870000.00-86.4% | $5133093000.00-82.8% | $29854003000.00 | — |
| Weighted average number of shares used in computing diluted loss per share of Common Stock (in Shares) | $1631037000.00+115.2% | $757749000.00-85.2% | $5133093000.00 | — | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-17 | 2026-03-18 | Yeganeh Reuven | Director | Sale | 530.0K | $5.00 | $2.65M | 0 | View | |
| 2026-03-16 | 2026-03-18 | Yeganeh Reuven | Director | Sale | 450.0K | $5.00 | $2.25M | 0 | View | |
| 2026-03-13 | 2026-03-13 | Yeganeh Reuven | Director | Sale | 370.0K | $5.00 | $1.85M | 0 | View | |
| 2026-03-12 | 2026-03-13 | Yeganeh Reuven | Director | Sale | 300.0K | $5.00 | $1.50M | 0 | View |
Informational purposes only, not investment advice.